Using the MicroCal PEAQ-ITC Instruments to Address the Needs of Drug Discovery

contributed by Malvern Panalytical | 07/03/2017

This white paper highlights the advantages of the new ITC instruments—MicroCal PEAQ-ITC and MicroCal PEAQ-ITC Automated systems and MicroCal PEAQ-ITC Analysis Software. The software allows analysis of binding interactions complicated by the presence of inactive protein material, incorrect protein concentration, and/or inaccurate concentration or heterogeneity of compound solutions.

Measurements and characterization of binding interactions between proteins and low-molecular weight ligands are fundamental for drug discovery. Among the most recognized challenges in characterizing binding interactions are(1) the need to accurately assess a wide span of binding affinities (K_D) and(2) accurately rank and characterize low-molecular weight (LMW) ligands based on affinity, mechanism of action, and energetics of interaction.

Reliable interpretation of binding data can be complicated by the presence of inactive protein fraction or inaccurate assessment of protein concentration. Assessment of this data can be further hampered by inherent uncertainty in concentration of compound stocks. This uncertainty results from inaccurate measurement, limited solubility, or potential chemical heterogeneity of the compounds such as presence of enantiomers and isomers.

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.